[TimAlerts] Ok found it.. from VBLT presentation : "VBL's lead VTS drug VB-111, is a gene-based biologic for the treatment of solid cancers. We investigated a super enhancer element of an exclusive role in the PPE-1 promoter’s specificity. We mapped key elements in this regulatory sequence, and generated a modified promoter as next-generation anti- angiogenic biological agent. Given as an IV infusion, VB-111 targets endothelial cells in the tumor vasculature, acting as a "biological knife". Moreover, VB-11